{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:00:49Z","timestamp":1792879249446,"version":"4.5.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Epilepsy is a common neurological disorder associated with recurring seizures that in about one-third of individuals are resistant to conventional medications. Neuroinflammation and alterations in the endocannabinoid system are involved in epileptogenesis and represent attractive targets for therapeutic interventions. Randomized placebo-controlled trials have shown that cannabidiol (CBD), one of the main active principles found in the\n                    <jats:italic>Cannabis<\/jats:italic>\n                    plant, significantly reduces seizure frequency in patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex (TSC). The FDA\u2019s approval of a purified formulation of CBD (Epidiolex\n                    <jats:sup>\u00ae<\/jats:sup>\n                    ) in 2018 marks a significant advance in the management of patients affected by these disorders. This review is focused on the activity of CBD as a neuroinflammatory modulator and antiseizure agent. Experimental evidence from\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    studies indicates that CBD reduces neuronal excitability and seizure activity by a wide range of mechanisms including, but not limited to, modulation of endocannabinoid, adenosine, GPR55, and TRPV1 receptors. It has also been shown that CBD\u2019s molecular actions trigger immunomodulatory effects and inhibit neuroinflammation through reduced concentrations of proinflammatory cytokines, chemokines, reactive oxygen species (ROS) and neurotoxic factors in microglia. We discuss the evidence for CBD\u2019s effects on neuroinflammation, and their implications for inhibition of epileptogenesis and seizure activity. We highlight how further elucidation of CBD\u2019s mechanisms of action, and particularly its effects on neuroinflammation, could lead to a more rational, targeted utilization of this compound, guided by assessment of biomarkers predictive of clinical response. Improved understanding of CBD\u2019s immunomodulatory and anti-inflammatory effects could also facilitate the design of controlled studies to confirm the potential value of this compound in the treatment of types of epilepsy beyond those for which regulatory approval has been already obtained.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2025.1749260","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:36:32Z","timestamp":1767594992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Epilepsy, neuroinflammation and cannabidiol What do we know thus far?"],"prefix":"10.3389","volume":"16","author":[{"given":"Gabriela","family":"Pes\u00e1ntez R\u00edos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caraballo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Pes\u00e1ntez R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. I.","family":"Pascual-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galo","family":"Pes\u00e1ntez Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6488","DOI":"10.3390\/ijms25126488","article-title":"A systematic review of the predictive and diagnostic uses of neuroinflammation biomarkers for epileptogenesis","volume":"25","author":"Aguilar-Castillo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/epi.13782","article-title":"Prospective clinical trials to investigate clinical and molecular biomarkers","volume":"58","author":"Auvin","year":"2017","journal-title":"Epilepsia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/epi.13785","article-title":"Neuroinflammation in epileptogenesis: insights and translational perspectives from new models of epilepsy","volume":"58","author":"Barker-Haliski","year":"2017","journal-title":"Epilepsia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1528-1157.2000.tb00166.x","article-title":"The cost of epilepsy in the United States: an estimate from population-based clinical and survey data","volume":"41","author":"Begley","year":"2000","journal-title":"Epilepsia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/epi.16542","article-title":"Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.bmc.2015.01.059","article-title":"Cannabidiol (CBD) and its analogs: a review of their effects on inflammation","volume":"23","author":"Burstein","year":"2015","journal-title":"Bioorg Med. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1111\/epi.18378","article-title":"Expanding the therapeutic role of highly purified cannabidiol in monogenic epilepsies: a multicenter real-world study","volume":"66","author":"Cerulli Irelli","year":"2025","journal-title":"Epilepsia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e70304","DOI":"10.1111\/ene.70304","article-title":"Assessing real world efficacy, safety, and 18-month retention rates of cannabidiol in individuals with drug resistant epilepsies","volume":"32","author":"Chemaly","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.3390\/ijms20236079","article-title":"The interplay between the endocannabinoid system, epilepsy and cannabinoids","volume":"20","author":"Cheung","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3349\/ymj.2008.49.1.1","article-title":"Role of brain inflammation in epileptogenesis","volume":"49","author":"Choi","year":"2008","journal-title":"Yonsei Med. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/epi.12635","article-title":"The case for assessing cannabidiol in epilepsy","volume":"55","author":"Cilio","year":"2014","journal-title":"Epilepsia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11286","DOI":"10.1038\/s41598-022-15134-5","article-title":"Effects of chronic cannabidiol in a mouse model of naturally occurring neuroinflammation, neurodegeneration, and spontaneous seizures","volume":"12","author":"Dearborn","year":"2022","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1152\/physrev.00049.2021","article-title":"Cannabinoid treatments in epilepsy and seizure disorders","volume":"104","author":"Devinsky","year":"2024","journal-title":"Physiol. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/glia.23738","article-title":"Cannabidiol prevents LPS-Induced microglial inflammation by inhibiting ROS\/NF-\u03baB-dependent signaling and glucose consumption","volume":"68","author":"Dos-Santos-Pereira","year":"2020","journal-title":"Glia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.seizure.2022.11.006","article-title":"Cannabidiol in refractory status epilepticus: a review of clinical experiences","volume":"103","author":"Duda","year":"2022","journal-title":"Seizure"},{"key":"B18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/epi4.12740","article-title":"Cannabidiol in the acute phase of febrile infection-related epilepsy syndrome (FIRES)","volume":"8","author":"Fetta","year":"2023","journal-title":"Epilepsia Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s40265-019-01171-4","article-title":"Pharmacological and therapeutic properties of cannabidiol for epilepsy","volume":"79","author":"Franco","year":"2019","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"108442","DOI":"10.1016\/j.neuropharm.2020.108442","article-title":"Cannabidiol in the treatment of epilepsy: current evidence and perspectives for further research","volume":"185","author":"Franco","year":"2021","journal-title":"Neuropharmacology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the treatment of epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.33588\/rn.5907.2014241","article-title":"Validez y consistencia de las escalas ECAVIPEP y CAVE para evaluar la calidad de vida en pacientes pedi\u00e1tricos con epilepsia","volume":"59","author":"Garc\u00eda-Galicia","year":"2014","journal-title":"Rev. Neurol."},{"key":"B23","first-page":"63","article-title":"Fracaso escolar y epilepsia infantil","volume":"60","author":"Garc\u00eda-Pe\u00f1as","year":"2015"},{"key":"B24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1684\/epd.2020.1135","article-title":"The proposed mechanism of action of CBD in epilepsy","volume":"22","author":"Gray","year":"2020","journal-title":"Epileptic Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/19390211.2020.1766634","article-title":"Content versus label claims in cannabidiol (CBD)-Containing products obtained from commercial outlets in the state of Mississippi","volume":"17","author":"Gurley","year":"2020","journal-title":"J. Diet. Suppl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2174\/1570159X20666220411101217","article-title":"The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol","volume":"21","author":"Hartmann","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s42466-025-00408-w","article-title":"Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies","volume":"7","author":"Hollander","year":"2025","journal-title":"Neurol. Res. Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s42238-025-00332-5","article-title":"The effects of cannabidiol on nitric oxide synthases: a narrative review on therapeutic implications for inflammation and oxidative stress in health and disease","volume":"7","author":"Hooshmand","year":"2025","journal-title":"J. Cannabis Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"109210","DOI":"10.1016\/j.yebeh.2023.109210","article-title":"Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy","volume":"144","author":"Kochen","year":"2023","journal-title":"Epilepsy Behav."},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/epi.13778","article-title":"Neuroinflammation imaging markers for epileptogenesis","volume":"58","author":"Koepp","year":"2017","journal-title":"Epilepsia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.14581\/jer.17003","article-title":"Could cannabidiol be a treatment option for intractable childhood and adolescent epilepsy","volume":"7","author":"Koo","year":"2017","journal-title":"J. Epilepsy Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.25956","article-title":"Prevention of epilepsy in infants with Tuberous Sclerosis complex in the EPISTOP trial","volume":"89","author":"Kotulska","year":"2021","journal-title":"Ann. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1074\/jbc.M109.069294","article-title":"Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta\/STAT proinflammatory pathways in BV-2 microglial cells","volume":"285","author":"Kozela","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fnins.2016.00323","article-title":"Effects of cannabidiol and hypothermia on short-term brain damage in new-born piglets after acute hypoxia-ischemia","volume":"10","author":"Lafuente","year":"2016","journal-title":"Front. Neurosci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"108156","DOI":"10.1016\/j.neuropharm.2020.108156","article-title":"Cannabidiol anticonvulsant effect is mediated by the PI3K\u03b3 pathway","volume":"176","author":"Lima","year":"2020","journal-title":"Neuropharmacology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.nrl.2014.04.012","article-title":"Drug-resistant epilepsy: definition and treatment alternatives","volume":"30","author":"L\u00f3pez Gonz\u00e1lez","year":"2015","journal-title":"Neurol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/j.1528-1167.2011.03325.x","article-title":"Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments","volume":"52","author":"Luoni","year":"2011","journal-title":"Epilepsia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.nbd.2013.06.016","article-title":"Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors","volume":"59","author":"Mecha","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1007\/s12035-021-02479-7","article-title":"Cannabidiol confers neuroprotection in rats in a model of transient global cerebral ischemia: impact of hippocampal synaptic neuroplasticity","volume":"58","author":"Meyer","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1871527315666160927110305","article-title":"Neuroprotective effects of cannabidiol in hypoxic ischemic insult. The therapeutic window in newborn mice","volume":"16","author":"Mohammed","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pnpbp.2016.11.005","article-title":"Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia","volume":"75","author":"Mori","year":"2017","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry."},{"key":"B43","first-page":"12","article-title":"Calidad de Vida en Ni\u00f1os con Epilepsia Resistente","author":"Moya","year":"2015","journal-title":"Rev. Chil. Epilepsia."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/epi.14685","article-title":"Validated outcome of treatment changes according to international league against epilepsy criteria in adults with drug-resistant focal epilepsy","volume":"60","author":"Mula","year":"2019","journal-title":"Epilepsia"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1684\/epd.2019.1124","article-title":"The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials","volume":"22","author":"Nabbout","year":"2020","journal-title":"Epileptic Disord."},{"key":"B46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.anpedi.2016.05.002","article-title":"Estudio de las epilepsias seg\u00fan la edad de inicio, controladas durante 3 a\u00f1os en una unidad de neuropediatr\u00eda de referencia regional","volume":"86","author":"Ochoa-G\u00f3mez","year":"2017","journal-title":"An Pediatr"},{"key":"B47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13311-014-0265-2","article-title":"Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile Infection-related epilepsy syndrome (FIRES)","volume":"11","author":"Pardo","year":"2014","journal-title":"Neurotherapeutics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3390\/molecules23051230","article-title":"Quality traits of \u201ccannabidiol oils\u201d: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations","volume":"23","author":"Pavlovic","year":"2018","journal-title":"Molecules"},{"key":"B49","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.neuropharm.2012.05.034","article-title":"Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function","volume":"63","author":"Pazos","year":"2012","journal-title":"Neuropharmacology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","article-title":"Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors","volume":"71","author":"Pazos","year":"2013","journal-title":"Neuropharmacology"},{"key":"B51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14581\/jer.17012","article-title":"Cannabinoids in the treatment of epilepsy: hard evidence at last? J","volume":"7","author":"Perucca","year":"2025","journal-title":"Epilepsy Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"epi4.70149","DOI":"10.1002\/epi4.70149","article-title":"Real-world efficacy and safety of cannabidiol in developmental and epileptic encephalopathies","author":"Perulli","year":"2025","journal-title":"Epilepsia Open"},{"key":"B53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuarg.2017.10.002","article-title":"Tuberous sclerosis in Ecuador. Case series report","volume":"10","author":"Pesantez","year":"2018","journal-title":"Neurol. Argent."},{"key":"B54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.33588\/rn.6504.2016573","article-title":"Cannabidiol: its use in refractory epilepsies","volume":"65","author":"Pes\u00e1ntez R\u00edos","year":"2017","journal-title":"Rev. Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.3390\/life12122065","article-title":"A pilot study on the use of low doses of CBD to control seizures in rare and severe forms of drug-resistant epilepsy","volume":"12","author":"Pes\u00e1ntez R\u00edos","year":"2022","journal-title":"Life (Basel)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40272-019-00341-x","article-title":"Purified cannabidiol for treatment of refractory epilepsies in pediatric patients with developmental and epileptic encephalopathy","volume":"21","author":"Pietrafusa","year":"2019","journal-title":"Paediatr. Drugs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejpn.2022.01.008","article-title":"Is cannabidiol worth a trial in rasmussen encephalitis?","volume":"37","author":"Prager","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B58","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.33588\/rn.64S03.2017162","article-title":"Encefalopat\u00edas epil\u00e9pticas","volume":"64","author":"Ramos-Lizana","year":"2017","journal-title":"Rev. Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12974-018-1192-7","article-title":"The role of inflammation in the development of epilepsy","volume":"15","author":"Rana","year":"2018","journal-title":"Neuroinflammation"},{"key":"B60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.115.230151","article-title":"The pharmacological basis of cannabis therapy for epilepsy","volume":"357","author":"Reddy","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"110590","DOI":"10.1016\/j.yebeh.2025.110590","article-title":"A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies","volume":"171","author":"Reyes","year":"2025","journal-title":"Epilepsy Behav."},{"key":"B62","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13311-015-0375-5","article-title":"Cannabinoids and epilepsy","volume":"12","author":"Rosenberg","year":"2015","journal-title":"Neurotherapeutics"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1111\/epi.13815","article-title":"Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"58","author":"Rosenberg","year":"2017","journal-title":"Epilepsia"},{"key":"B64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.seizure.2025.10.001","article-title":"Efficacy and safety of cannabidiol in children with developmental and epileptic encephalopathies: a systematic review","volume":"133","author":"Saranti","year":"2025","journal-title":"Seizure"},{"key":"B65","first-page":"512","article-title":"ILAE cassification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2018"},{"key":"B66","doi-asserted-by":"publisher","first-page":"109606","DOI":"10.1016\/j.yebeh.2023.109606","article-title":"The longitudinal effects of cannabidiol on brain temperature in patients with treatment-resistant epilepsy","volume":"151","author":"Sharma","year":"2024","journal-title":"Epilepsy Behav."},{"key":"B67","doi-asserted-by":"publisher","first-page":"110641","DOI":"10.1016\/j.yebeh.2025.110641","article-title":"Identification of neuro-inflammatory biomarkers through non-invasive advanced neuroimaging techniques in pharmaco-resistant epilepsy: a systematic review","volume":"171","author":"Shoukair","year":"2025","journal-title":"Epilepsy Behav."},{"key":"B68","doi-asserted-by":"publisher","first-page":"102634","DOI":"10.1016\/j.pneurobio.2024.102634","article-title":"TRPV1 channel in the pathophysiology of epilepsy and its potential as a molecular target for the development of new antiseizure drug candidates","volume":"240","author":"Soca\u0142a","year":"2024","journal-title":"Prog. Neurobiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"107869","DOI":"10.1016\/j.yebeh.2021.107869","article-title":"Behavioral comorbidities of epilepsy and neuroinflammation: evidence from experimental and clinical studies","volume":"117","author":"Suleymanova","year":"2021","journal-title":"Epilepsy Behav."},{"key":"B70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s42238-025-00274-y","article-title":"Beyond the hype: a comprehensive exploration of CBD's biological impacts and mechanisms of action","volume":"7","author":"Swenson","year":"2025","journal-title":"J. Cannabis Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pediatrneurol.2022.06.016","article-title":"The long-term effectiveness and safety of cannabidiol-enriched oil in children with drug-resistant epilepsy","volume":"136","author":"Tzadok","year":"2022","journal-title":"Pediatr. Neurol."},{"key":"B72","unstructured":"Warning letters for cannabis-derived products\n          \n          \n          2025"},{"key":"B73","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1055\/a-2534-3267","article-title":"Management of developmental and epileptic encephalopathies","volume":"45","author":"Vasquez","year":"2025","journal-title":"Semin. Neurol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"a022699","DOI":"10.1101\/cshperspect.a022699","article-title":"Immunity and inflammation in epilepsy","volume":"18","author":"Vezzani","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41582-019-0217-x","article-title":"Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy","volume":"15","author":"Vezzani","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2022.06.010","article-title":"Prophylactic administration of cannabidiol reduces microglial inflammatory response to kainate-induced seizures and neurogenesis","volume":"500","author":"Victor","year":"2022","journal-title":"Neuroscience"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/epi.13057","article-title":"Summary of recommendations for the management of infantile seizures: task force report for the ILAE commission of pediatrics","volume":"56","author":"Wilmshurst","year":"2015","journal-title":"Epilepsia"},{"key":"B78","volume-title":"Epilepsy: a public health imperative","year":"2019"},{"key":"B79","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.3390\/molecules27154961","article-title":"Neuroprotection of cannabidiol, its synthetic derivatives and combination preparations against microglia-mediated neuroinflammation in neurological disorders","volume":"27","author":"Yousaf","year":"2022","journal-title":"Molecules"},{"key":"B80","doi-asserted-by":"publisher","first-page":"12689","DOI":"10.3390\/ijms241612689","article-title":"Neuroinflammatory dysfunction of the blood-brain barrier and basement membrane dysplasia play a role in the development of drug-resistant epilepsy","volume":"24","author":"Zabrodskaya","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1749260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:36:35Z","timestamp":1767594995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1749260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":80,"alternative-id":["10.3389\/fphar.2025.1749260"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1749260","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1749260"}}